Inhibitory receptors as targets for cancer immunotherapy
about
Harnessing the immune system to improve cancer therapyAdverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case ReportsEmerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsAggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis.Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.Genetic and Epigenetic Regulation of PD-1 ExpressionEmerging Opportunities and Challenges in Cancer Immunotherapy.Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement.LAG3 (CD223) as a cancer immunotherapy target.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.Signals that drive T follicular helper cell formation.Immunoproteasomes edit tumors, which then escapes immune recognitionDownregulated IL-21 Response and T Follicular Helper Cell Exhaustion Correlate with Compromised CD8 T Cell Immunity during Chronic Toxoplasmosis.Highly aggressive rat prostate tumors rapidly precondition regional lymph nodes for subsequent metastatic growth.Translating Mouse Models.Facial diplegia after pembrolizumab treatment.Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer.Bilateral anterior uveitis after immunotherapy for malignant melanoma
P2860
Q26738698-B2E9B17C-7EBF-401E-BAA7-88A3AC89C6FAQ28553328-95A99313-C55E-4F99-87D2-F1E6D9C3BCC5Q33833475-E9911A5E-5E29-4D86-87EB-2CEBD736F6BDQ36363019-DCB9F52A-B4D0-40F5-BF42-F31E6E7AF60DQ38687631-A4D8165F-20CE-40FE-94C9-66C4686CE445Q38698632-7BF2A88A-58C0-4709-8E71-8B05080897C3Q38761535-4F8C25AD-0D09-48AE-B6A1-B006FFB59BC2Q38809772-F90D9CA7-B69F-489E-8318-3B8892E4AF9BQ39090226-0FEA9C6B-255C-413E-9A2C-23F4EB68F821Q39160974-50F850EF-A432-435F-AE88-D022513E6B3EQ39237785-BAEB9B3A-BBF0-42CD-992E-49740EDEDD9DQ39382728-F359DFE0-75CB-471E-83CA-CF8C378902C9Q41497500-7DE72086-209B-40C6-B9A3-55087C0331E8Q46165473-D4B762FA-FFC8-4E24-97E1-9A4BAE869C56Q46166018-8F600C2F-B6D3-44DD-9336-E9E7E2561767Q46463280-81FEA9BB-ADF3-4125-A0DF-9F63E60A9C2AQ48290401-01FD9585-BF0B-4B04-B757-4BC80D617DFDQ55391924-073CA910-0CBB-4914-AAA2-F4DBF1CACFBBQ57193038-2807A9FC-B8AA-4D61-86B4-FFCB62AB07D3
P2860
Inhibitory receptors as targets for cancer immunotherapy
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Inhibitory receptors as targets for cancer immunotherapy
@ast
Inhibitory receptors as targets for cancer immunotherapy
@en
type
label
Inhibitory receptors as targets for cancer immunotherapy
@ast
Inhibitory receptors as targets for cancer immunotherapy
@en
prefLabel
Inhibitory receptors as targets for cancer immunotherapy
@ast
Inhibitory receptors as targets for cancer immunotherapy
@en
P2093
P2860
P356
P1476
Inhibitory receptors as targets for cancer immunotherapy
@en
P2093
Dario A A Vignali
Lawrence P Andrews
Meghan E Turnis
P2860
P304
P356
10.1002/EJI.201344413
P407
P577
2015-07-01T00:00:00Z